| 14.36 0.63 (4.59%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 18.78 | 1-year : | 21.93 |
| Resists | First : | 16.07 | Second : | 18.78 |
| Pivot price | 13.54 |
|||
| Supports | First : | 12.71 |
Second : | 10.64 |
| MAs | MA(5) : | 13.53 |
MA(20) : | 13.54 |
| MA(100) : | 11.07 |
MA(250) : | 8.18 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3  |
| %K %D | K(14,3) : | 38.9 |
D(3) : | 28 |
| RSI | RSI(14): 64.3 |
|||
| 52-week | High : | 16.07 | Low : | 2.21 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PHAT ] has closed It is unclear right now based on current values. 54.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.49 - 14.55 | 14.55 - 14.61 |
| Low: | 13.68 - 13.74 | 13.74 - 13.8 |
| Close: | 14.26 - 14.37 | 14.37 - 14.47 |
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Mon, 03 Nov 2025
Phathom Pharmaceuticals (Nasdaq: PHAT) to join 5 investor conferences; 90‑day webcasts - Stock Titan
Mon, 03 Nov 2025
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Sat, 01 Nov 2025
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2025 Earnings Call Transcript - Insider Monkey
Thu, 30 Oct 2025
Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance
Tue, 28 Oct 2025
With 51% ownership of the shares, Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is heavily dominated by institutional owners - Yahoo Finance
Sat, 25 Oct 2025
Phathom Pharmaceuticals Publishes Positive Phase 3 Trial Results for VOQUEZNA® in Treating Nighttime GERD Symptoms - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 82.8 (%) |
| Shares Short | 14,130 (K) |
| Shares Short P.Month | 14,000 (K) |
| EPS | -4.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -5.79 |
| Profit Margin | -289.6 % |
| Operating Margin | -151.7 % |
| Return on Assets (ttm) | -59.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 439.3 % |
| Gross Profit (p.s.) | 1.39 |
| Sales Per Share | 1.6 |
| EBITDA (p.s.) | -3.79 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -275 (M) |
| Levered Free Cash Flow | -191 (M) |
| PE Ratio | -3.08 |
| PEG Ratio | 0 |
| Price to Book value | -2.49 |
| Price to Sales | 8.93 |
| Price to Cash Flow | -3.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|